Bullish Case: AVY beat Q2 (EPS $2.89, rev $2.5B, +4.6% pop) with FY EPS guided $10.00–$10.30; mean target $199 (+17.5%) with JPM at $190 and UBS at $225. Call volume runs 54% above puts and bullish risk exceeds bearish by 11% across tenors. The Helium density peaks near $170 with a secondary shoulder at $185, and ATM IV in the mid-20s (~26–27 at Jan-2027 strikes) is modest — a reclaim of $175–180 on contained IV supports a re-rate toward $185+.

Bearish Case: AVY still sits -24% from five years ago, -22% over two years, and underperformed SPX badly (5.3% vs 18.7%); the tape is flat and -5.4% over the past month. The Helium AI forecast is -0.73% with -0.1 realized correlation. Put skew persists (Oct 150P at 29% IV vs 28% for ATM), the term structure is in backwardation, and the Helium density carries non-trivial mass at $150–160, leaving room for demand softness to reprice the stock lower.

Potential Outcomes: Calibration note: prior base-case ranges (165–175) tracked well; earlier 170–178 upside calls underperformed — discount bullishness accordingly.

1. 40% Range 160–178: drift near $169; IV backwardation eases, Q3 print (late Oct) is the pivot.
2. 30% Upside 180–195: Q3 beat + RFID/Steri traction, IV compresses, JPM $190 magnet.
3. 20% Downside 150–160: consumer/label demand cracks; put skew steepens (Oct 150P IV >29%).
4. 6% Tail < $140: macro risk-off; SPY surface shows left-tail vol>35%.
5. 4% Tail > $200: upgrade cycle toward UBS $225.

Oracle: defined-risk Oct/Jan spreads — e.g., Jan-2027 165/185 call spread financed vs 145 puts; size small into Q3 earnings (falsifiable: lose <160 invalidates bull path).

September 12, 2026